<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772563</url>
  </required_header>
  <id_info>
    <org_study_id>1230.24</org_study_id>
    <secondary_id>2011-002367-23</secondary_id>
    <nct_id>NCT01772563</nct_id>
  </id_info>
  <brief_title>Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours</brief_title>
  <official_title>An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the present study is to investigate the influence of&#xD;
      co-administration of itraconazole and volasertib on the pharmacokinetic profile of volasertib&#xD;
      without co-administration of itraconazole. Secondary objectives are to investigate safety,&#xD;
      tolerability and preliminary therapeutic effects following intravenous administration of&#xD;
      volasertib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2013</start_date>
  <completion_date type="Actual">April 22, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the plasma concentration-time curve over the time interval from zero to the last quantifiable drug plasma concentration after dose administration (AUC0-tz)</measure>
    <time_frame>up to 504 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum measured plasma concentration (Cmax)</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-infinity)</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with significant abnormalities in electrocardiogram results</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurance of significant changes from baseline laboratory measurements</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>volasertib + itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of volasertib alone and in combination with itraconazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volasertib</intervention_name>
    <description>cycle in 21 days</description>
    <arm_group_label>volasertib + itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>over 18 days</description>
    <arm_group_label>volasertib + itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with histologically or cytologically confirmed diagnosis of advanced, non&#xD;
             resectable and / or metastatic solid tumour, for whom conventional treatment has&#xD;
             failed, or for whom no therapy of proven efficacy exists, or who are not amenable to&#xD;
             established forms of treatment based on the investigator's assessment&#xD;
&#xD;
          2. Male or female&#xD;
&#xD;
          3. Age =&gt;18 and =&lt;70 years&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance score =&lt; 2&#xD;
&#xD;
          5. Recovery from Common Terminology Criteria for Adverse Events (CTCAE) Grade &gt;= 2&#xD;
             therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapy&#xD;
             (except alopecia)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Serious concomitant non-oncological disease considered by the investigator to be&#xD;
             incompatible with the protocol&#xD;
&#xD;
          2. Active infectious disease&#xD;
&#xD;
          3. Viral hepatitis, HIV infection&#xD;
&#xD;
          4. Clinical evidence of active brain metastasis or leptomeningeal disease during the past&#xD;
             6 months&#xD;
&#xD;
          5. Second malignancy currently requiring active therapy (except for hormonal /&#xD;
             antihormonal treatment e.g. in prostate or breast cancer)&#xD;
&#xD;
          6. Absolute neutrophil count less than 1,500/mm3&#xD;
&#xD;
          7. Platelet count less than 100,000/mm3&#xD;
&#xD;
          8. Total bilirubin greater than 1.5 mg/dL (&gt; 26 Âµmol/L, SI unit equivalent)&#xD;
&#xD;
          9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater&#xD;
             than 2.5 times the upper limit of normal (if related to liver metastases greater than&#xD;
             five times the upper limit of normal)&#xD;
&#xD;
         10. Serum creatinine greater than 2x upper limit of normal (ULN)&#xD;
&#xD;
         11. QTcF prolongation &gt; 470 ms or QT prolongation deemed clinically relevant by the&#xD;
             investigator (e.g., congenital long QT syndrome).The QTcF will be calculated as the&#xD;
             mean of the 3 ECGs taken at screening&#xD;
&#xD;
         12. Female patients with childbearing potential and unwilling to use a medically&#xD;
             acceptable method of contraception during the trial and for at least six months after&#xD;
             end of active therapy. Woman of childbearing potential (premenopausal female) is&#xD;
             defined as the female who is not surgically sterilised by hysterectomy or bilateral&#xD;
             tubal ligation or post-menopausal for at least 12 months.&#xD;
&#xD;
         13. Treatment with other investigational drugs or participation in another clinical trial&#xD;
             within the past four weeks prior to start of therapy or concomitantly with this trial&#xD;
&#xD;
         14. Chemo-, radio- immuno-, or molecular-targeted cancer-therapy within the past four&#xD;
             weeks prior to start of therapy or concomitantly with this trial. This restriction&#xD;
             does not apply to steroids, bisphosphonates hormonal / antihormonal treatment (e.g. in&#xD;
             prostate or breast cancer).&#xD;
&#xD;
         15. Alcohol abuse more than an average 3 units of alcoholic beverages per day or more than&#xD;
             21 units per week (1 unit equals 0.5 pint [285 mL] of beer or lager, 1 glass [125 mL]&#xD;
             of wine, 25 mL shot of 40% spirit) or drug abuse&#xD;
&#xD;
         16. Life expectancy less than 12 weeks&#xD;
&#xD;
         17. Potent CYP 3A4 and P-glycoprotein inhibitors other than the study drug or inducers&#xD;
             between one week prior to first drug administration or expected treatment with a&#xD;
             respective drug until the last PK sample is collected&#xD;
&#xD;
               1. Strong CYP 3A4 inhibitors: atazanavir, clarithromycin, indinavir, itraconazole&#xD;
                  (other then study drug), ketoconazole, nefazodone, nelfinavir, ritonavir,&#xD;
                  saquinavir, telithromycin&#xD;
&#xD;
               2. CYP 3A4 inducers: carbamazepine, rifampicin&#xD;
&#xD;
               3. P-gp inhibitors: cyclosporine, erythromycin, itraconazole (other then study&#xD;
                  drug), ketoconazole, quinidine, phenobarbital salt with quinidine, ritonavir,&#xD;
                  valspodar, verapamil&#xD;
&#xD;
               4. P-gp inducers: hypericum perforatum, rifampicin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Hungary Ltd., Phase I. Clinical Pharmacology Unit</name>
      <address>
        <city>Budapest</city>
        <zip>1077</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

